Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Leases (2017 - 2025)

Historic Leases for BeOne Medicines (BEIGF) over the last 9 years, with Q3 2025 value amounting to $140.2 million.

  • BeOne Medicines' Leases rose 3876.55% to $140.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.2 million, marking a year-over-year increase of 3876.55%. This contributed to the annual value of $139.3 million for FY2024, which is 4632.22% up from last year.
  • As of Q3 2025, BeOne Medicines' Leases stood at $140.2 million, which was up 3876.55% from $145.8 million recorded in Q2 2025.
  • BeOne Medicines' Leases' 5-year high stood at $146.4 million during Q1 2025, with a 5-year trough of $86.9 million in Q1 2021.
  • For the 5-year period, BeOne Medicines' Leases averaged around $111.6 million, with its median value being $109.0 million (2023).
  • As far as peak fluctuations go, BeOne Medicines' Leases plummeted by 1949.0% in 2024, and later soared by 6686.15% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Leases stood at $117.4 million in 2021, then decreased by 6.36% to $110.0 million in 2022, then dropped by 13.42% to $95.2 million in 2023, then soared by 46.32% to $139.3 million in 2024, then rose by 0.65% to $140.2 million in 2025.
  • Its last three reported values are $140.2 million in Q3 2025, $145.8 million for Q2 2025, and $146.4 million during Q1 2025.